Ragan PR Daily Names The TASC Group One of The Top Places to Work in Communications in 2025
The nonprofit communications and public relations firm was recognized for its employee benefits and dynamic workplace culture
NEW YORK, April 8, 2025 /PRNewswire/ -- Ragan PR Daily recognized The TASC Group, a nonprofit communications and public relations firm, as one of the Top Places to Work in Communications in 2025. The award recognizes companies for exceptional onboarding programs, training and development, workplace benefits and cultivating dynamic and supportive workplaces.
The TASC Group (TASC) is an independent, full-service nonprofit communications and public relations firm. For over twenty years, The TASC Group has provided comprehensive communications services to a broad spectrum of mission-driven clients spanning the nonprofit, philanthropic and social justice spaces.
"We are incredibly honored to be recognized as one of the Top Places to Work in Communications by Ragan PR Daily," said Rida Bint Fozi, president and partner at The TASC Group. "This recognition reflects the extraordinary work of our talented staff. We strive to create a workplace where everyone feels valued and supported."
At The TASC Group, team members enjoy a comprehensive benefits package including generous PTO, summer Fridays, a 401k plan, excellent healthcare, a hybrid work schedule and a wellness stipend, encouraging employees to prioritize their mental and physical health. TASC also offers a professional development stipend, empowering employees to learn new skills and advance their careers through continued education.
The TASC Group has received consistent recognition for both its dynamic workplace and its excellence in nonprofit communications and cause-driven PR. Last year, Observer recognized TASC as a Top Nonprofit PR Firm and Ragan PR Daily named TASC one of its Top Agencies. In 2023, Business Insider named TASC one of its top 15 boutique PR firms, Inc. Magazine included TASC on its Inc. 5000 list of fastest-growing companies. TASC has also won 26 PRSA Big Apple Awards.
Some of The TASC Group's most notable nonprofit and social justice clients include the Trayvon Martin family and their legal team, the Columbia Journalism School, a consortium of asbestos litigation law firms representing cancer victims of Johnson & Johnson and Georgia-Pacific, The David Lynch Foundation and Destination Tomorrow.
Media interested in learning more about The TASC Group should contact Kyle McIntyre at kyle@thetascgroup.com or (646) 639-1379.
For more information, visit www.thetascgroup.com.
Contact: Kyle McIntyrePhone: (646) 639-1379Email: kyle@thetascgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ragan-pr-daily-names-the-tasc-group-one-of-the-top-places-to-work-in-communications-in-2025-302422354.html
SOURCE The TASC Group
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Premium brand pet food plant opens in Rockingham County
ROCKINGHAM COUNTY, N.C. (WGHP) — A premium brand pet food plant is coming to the Triad all the way from Italy. Farmina Pet Foods will be opening its first-ever U.S. manufacturing plant in Rockingham County. It's a major investment for the region. FPF's owner and CEO, Dr. Angelo Russo, said that it was North Carolina's hospitality, good conditions for economic growth and an abundance of qualified workers that stood out to them. For Rockingham County, it will bring up to 300 more jobs and technologies from around the world. North Carolina Senator Phil Berger said now is a fascinating time for the pet industry. 'Fewer people are having kids, but … more getting dogs … and cats. I don't want to forget about our feline friends, but it's something people care a great deal about,' Berger said. Berger described FPF as one of the most reputable pet food brands that will bring a lot of growth to the local economy. 'Good, high-paying manufacturing jobs. Great for Rockingham County,' he said. In Reidsville, FPF will be opening its first U.S. manufacturing facility, and they have ambitious plans to deliver the best quality pet foods. FPF's North America CEO, Loris Rinaldi, said it was a $115 million investment. He is confident that it will be worth it for both the company and the county. 'This facility is designed to expand and have three times the production capacity we have today, and that additional investment is for the 300 people that will run this facility 24/7,' Rinaldi said. The facility will run with some cutting-edge technology. 'All of our bags are packed with nitrogen, which keeps everything fresh until you open the bag,' Rinaldi said. After having facilities in Italy and South America, this would be FPF's fifth facility, and they could not have found a better place to start off their North American venture. 'Your kind welcome … Economically speaking, the good conditions you give to us and a lot of qualified workers,' Russo said. Russo said this is just the beginning of the journey. According to Rinaldi, they will import machines from Japan, Italy and France for their technology. FPF's production will begin in July. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
20 minutes ago
- Yahoo
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James
Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the 13 Biotech Stocks with Huge Upside Potential. Raymond James has started coverage of Avidity Biosciences, Inc. (NASDAQ:RNA), with a Strong Buy rating and a price objective of $65. A scientist holding a vial of a promising product candidate for therapeutic development. The rating is part of a larger biotech sector note, in which the firm sees favorable risk/reward across the board. Raymond James points out that less de-risked platforms can produce the most outsized returns, even if companies with de-risked, high probability-of-success assets are frequently viewed with greater certainty. The firm stresses its confidence in del-zota, which is anticipated to be the first medicine from Avidity Biosciences, Inc. (NASDAQ:RNA)'s antibody oligonucleotide conjugate (AOC) platform to be approved. Avidity Biosciences, Inc. (NASDAQ:RNA) is becoming more well-known for its AOC platform, which targets muscle disorders by combining oligonucleotides and antibodies. According to Raymond James, one of the platform's top candidates, Del-Zota, has a strong chance of being approved. The $65 objective is in line with the firm's opinion that early-stage, less-risked assets can yield higher returns and points out faith in the platform's revolutionary potential. Avidity Biosciences, Inc. (NASDAQ:RNA) is a biopharmaceutical firm dedicated to developing a novel type of RNA treatment known as Antibody Oligonucleotide Conjugates, or AOCs. While we acknowledge the potential of RNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
Yahoo
22 minutes ago
- Yahoo
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
